David Hutton

In recognition of global Geographic Atrophy Week, Prevent Blindness is providing free educational resources on GA for patients, care partners and healthcare professionals

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

At AAO 2023, Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept for diabetic macular oedema

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualisation and patients who have undergone small aperture IOL implantation at this year's American Academy of Ophthalmology meeting

A patient filed a complaint in June 2019 claiming their medical records had been accessed by an NHS employee

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Penny Asbell, MD, FACS, presented results from the ARMOR Study

At this year's American Academy of Ophthalmology meeting, the Ophthalmology Times team spoke with Megan Baldwin, MD, founder of Opthea Limited, about the company's ShORe and COAST clinical trials

At AAO 2023, Rich Small, CEO of Neurotech, spoke with our team about the company's development of encapsulated cell therapy, NT-501

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

At this year's American Academy of Ophthalmology meeting, Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America, spoke with us about three exciting new launches

Ben Bergo, CEO of Visus Therapeutics, spoke with Ophthalmology Times about the BRIO-I study on presbyopia

Researchers from Anglia Ruskin University and the University of Oxford conducted a study that reveals knowledge gaps for conditions that affect 18-64-year-olds in the UK

In a conversation with Ophthalmology Times, Mary Elizabeth Hartnett, MD, FACS, discussed her AAO presentation, focusing on the impact of blindness and vision loss on women in the United States

Esen K. Akpek, MD, discussed her presentation at this year's American Academy of Ophthalmology meeting, covering recent advancements in artificial corneas

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

Surgeons can save space and optimise workflow efficiency in the operating room

The collection at the Truhlsen-Marmor Museum of the Eye includes more than 38,000 objects, including rare books, instruments and immersive educational materials.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular oedema

The patent is also being prosecuted in the European Union and around the globe

Mutations in the EMC1 gene appear to be associated with familial exudative vitreoretinopathy (FEVR), a severe ocular condition.

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery"

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents

Research from Orbis International analyses the overall wellbeing of children with common childhood vision problems

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution), commercialised as EvoTears in Europe, is the first prescription eye drop that targets tear evaporation.

The company has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.

According to the company, the deal expands its European footprint into Spain and Portugal.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!